

Plasma concentrations of 5-fluorouracil and F- β -alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil

Y Yamada^{*,1}, T Hamaguchi¹, M Goto¹, K Muro¹, Y Matsumura¹, Y Shimada¹, K Shirao¹ and S Nagayama²

¹Medical Oncology Division, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan; ²Taiho Pharmaceutical Co., Ltd. Pharmacokinetics Research Lab, 224-2 Ebisuno, Hiraishi, Kawauchi-cho, Tokushima 771-0194, Japan

The pharmacokinetics and pharmacodynamics of oral S-1, a dihydropyrimidine dehydrogenase (DPD) inhibitory fluoropyrimidine, were compared with those of protracted venous infusion (PVI) of 5-fluorouracil (5-FU). In all, 10 patients with gastric cancer received PVI of 5-FU at a dose of 250 mg m⁻² day⁻¹ for 5 days. After a washout period of 9 days, the patients received two divided doses daily for 28 days. S-1 was administered orally at about 0900 and 1900 hours. The daily dose of S-1 in terms of tegafur was 80 mg day⁻¹ in patients with a body surface area (BSA) of < 1.25 m², 100 mg day⁻¹ in those with a BSA of \geq 1.25 m² to < 1.5 m², and 120 mg day⁻¹ in those with a BSA of \geq 1.5 m². Plasma concentrations of 5-FU and F- β -alanine (FBAL) were measured for pharmacokinetic analysis, and the plasma uracil concentration was monitored as a surrogate marker of DPD inhibition (pharmacodynamic analysis) in the same patients on days 1–5 of PVI of 5-FU and on days 1–5 of oral S-1. The area under the curve (AUC_{0–10h}) of 5-FU on day 5 was 728 \pm 113 ng h ml⁻¹ for PVI of 5-FU and 1364 \pm 374 ng h ml⁻¹ for S-1. The median 5-FU PVI:S-1 ratio of the AUC_{0–10h} of 5-FU was 1.9. The AUC_{0–10h} of FBAL on day 5 of PVI of 5-FU was 9465 \pm 3225 ng h ml⁻¹, AUC_{0–10h}, as compared with 1725 \pm 605 ng h ml⁻¹ on day 5 of S-1 treatment. The AUC_{0–10h} of uracil on day 5 was 252 \pm 60 ng h ml⁻¹ with PVI of 5-FU and 12 582 \pm 3060 ng h ml⁻¹ with S-1. The AUC_{0–10h} of FBAL was markedly lower and plasma uracil concentrations were significantly higher for S-1 than for PVI of 5-FU, clearly demonstrating the effect of DPD inhibition.

British Journal of Cancer (2003) 89, 816–820. doi:10.1038/sj.bjc.6601224 www.bjcancer.com
© 2003 Cancer Research UK

Keywords: dihydropyrimidine dehydrogenase; 5-FU; pharmacokinetics; S-1

Continuous protracted intravenous infusion (PVI) of 5-fluorouracil (5-FU) has a higher response rate, less frequent haematologic toxicity (mainly neutropenia), and more frequent hand–foot syndrome (HFS) than bolus injection of 5-FU in patients with metastatic colorectal cancer (The Meta-Analysis Group in Cancer, 1998). Hand–foot syndrome and stomatitis each occur in about 23% of patients given 5-FU by PVI, whereas grade 3 leukopenia develops in only 1%. Most patients who receive 5-FU by PVI have no severe toxicity; the dose-limiting toxicity (DLT) is HFS (Lokich *et al*, 1989). Previous clinical trials have shown that PVI of 5-FU is one of the most effective and safest regimens. However, PVI requires a central venous catheter as well as an ambulatory pump, which is expensive and may lead to complications, and adversely affect patients' quality of life.

Oral fluoropyrimidine derivatives have been developed to circumvent the problems associated with PVI of 5-FU. S-1 is one such derivative that combines tegafur with two modulators of 5-FU metabolism, 5-chloro-2,4-dihydroxypyridine (CDHP), a reversible

inhibitor of dihydropyrimidine dehydrogenase (DPD), and potassium oxonate, in a molar ratio of 1:0.4:1. Tegafur, an oral prodrug of 5-FU, is gradually converted to 5-FU and rapidly metabolised by DPD in the liver. The DPD-inhibitory activity of CDHP is 180-fold higher than that of uracil, confirmed to be an effective DPD inhibitor in the form of uracil/tegafur (UFT) *in vitro*. Potassium oxonate is an orotate phosphoribosyl transferase inhibitor that is distributed primarily to the gastrointestinal tract. This component of S-1 decreases the incorporation of 5-fluorouridine triphosphate into RNA in the gastrointestinal mucosa and reduces the incidence of diarrhoea.

F- β -alanine (FBAL) is a main metabolite of 5-FU. F- β -alanine and fluorocitrate are thought to cause the cardiotoxic and neurotoxic effects of 5-FU by inhibiting the tricarboxylic acid cycle (Koenig and Patel, 1970; Okeda *et al*, 1990; Robben *et al*, 1993; Diasio, 1998; Kuwata *et al*, 2000; Kato *et al*, 2001). The CDHP component of S-1 inhibits DPD, the rate-limiting enzyme in the catabolic pathway of 5-FU. Consequently, the plasma FBAL concentration after oral administration of S-1 is significantly lower than that after PVI of 5-FU. However, information on plasma FBAL concentrations in patients given 5-FU remains scant (Van Kuilenberg *et al*, 2001).

*Correspondence: Y Yamada; E-mail: yayamada@ncc.go.jp

Received 25 November 2002; revised 3 June 2003; accepted 29 June 2003

The objectives of this study were to investigate differences in pharmacokinetics (PK) and pharmacodynamics (PD) between oral S-1 and PVI of 5-FU and to examine the DPD inhibitory activity of S-1.

MATERIALS AND METHODS

Anticancer drugs

S-1 capsules combining tegafur, CDHP, and potassium oxonate in a molar ratio of 1:0.4:1 (Taiho Pharmaceutical Co. Ltd., Tokyo, Japan) were used. Each capsule contained 20 or 25 mg of tegafur. 5-Fluorouracil was obtained from Kyowa Hakko Co., Ltd. (Tokyo, Japan).

Patients

In all, 10 consecutive patients with histologically proven metastatic gastrointestinal cancer were enrolled into this pharmacokinetic study. All patients were between 20 and 75 years of age and had an Eastern Cooperative Group (ECOG) performance status of 0–2, adequate baseline bone marrow (WBC count $3500 \mu\text{l}^{-1}$ or more and platelet $100\,000 \mu\text{l}^{-1}$ or more, hepatic (serum bilirubin level 1.5 mg dl^{-1} or less, and serum GOT and GPT 40 U l^{-1} or less), and renal (serum creatinine level 1.2 mg dl^{-1} or less) function, and a life expectancy of at least 12 weeks.

Patients were excluded if they had symptomatic brain metastasis or other serious concurrent disease. This study was approved by the institutional review board of the National Cancer Center Hospital. Written informed consent was obtained from each patient before enrolment.

Study design

All 10 patients received 5-FU by PVI at a rate of $250 \text{ mg m}^{-2} \text{ day}^{-1}$ via a peripheral vein. Infusion was carried out with the use of a battery-operated pump (STC-508, Terumo Co., Ltd., Tokyo, Japan) for five consecutive days. The assigned daily dose of 5-FU was diluted in 500 ml of normal saline for infusion. After a washout period of 9 days, patients received S-1 in two divided doses daily for 28 consecutive days. S-1 was administered orally within 1 h after breakfast and supper, at about 0900 and 1900 hours. The daily dose of S-1 in terms of tegafur was 80 mg day^{-1} in patients with a body surface area (BSA) of $<1.25 \text{ m}^2$, 100 mg day^{-1} in those with a BSA of $\geq 1.25 \text{ m}^2$ to $<1.5 \text{ m}^2$, and 120 mg day^{-1} in those with a BSA of $\geq 1.5 \text{ m}^2$.

Blood and urine sample collection

On days 1 and 5 of 5-FU PVI, blood samples were taken at 0 (before administration), 2, 6, and 10 h after the start of the infusion (0900 hours in all patients). On days 2–4, one blood sample was obtained at 0900 hours before the start of the next 24-h cycle. During oral administration of S-1, blood samples were taken on day 1 before the first dose of the day and at 1, 2, 4, 6, and 10 h. On days 2–4 of S-1 treatment, blood samples were taken before administration in the morning and at 4 and 10 h. On day 5, blood samples were obtained at 0, 2, 4, and 10 h. Peripheral blood samples (6 ml per sampling time) were collected in heparinised tubes and centrifuged at 1000 g for 15 min at 4°C . The plasma was stored at -20°C until analysis. Urine was collected from 0 to 24 h after the start of drug administration on day 1 of each treatment and refrigerated during the collection period.

Assay of 5-FU, uracil, and FBAL

Analysis of 5-FU and uracil was carried out as described by Matsushima *et al* (1997), with minor modification. 5-Fluorouracil

and uracil were extracted with ethyl acetate after washing with dichloromethane and were subjected to a reaction to induce their trimethylsilyl derivatives. 5-Fluorouracil and uracil were analysed by electron impact ionisation gas-chromatography/mass-spectrometry (GC–MS). For analysis of 5-FU by GC–MS, stable isotopes were used as internal standards. The measurable ranges of plasma or urine levels were $1\text{--}400 \text{ ng ml}^{-1}$ for 5-FU and $5\text{--}2000 \text{ ng ml}^{-1}$ for uracil. For analysis of FBAL, plasma was deproteinised with ethanol and washed with dichloromethane. F- β -alanine was treated with 2,4-dinitrofluorobenzene to derive its dinitrophenyl ester, and the reaction product was extracted with dichloromethane under acidic conditions. The reaction product was separated by high-pressure liquid chromatography (LC) with a reversed-phase column, and LC/tandem-mass spectrometry was performed with the use of negative ion-electron spray ionisation. DL-norvaline was used as an internal standard. The measurable range of plasma or urine levels was $5\text{--}2000 \text{ ng ml}^{-1}$ for FBAL.

Pharmacokinetics

Maximum plasma concentrations (C_{max}) were determined from the observed highest concentration after treatment with PVI of 5-FU or oral S-1. The area under the curve (AUC) was calculated from 0 to 10 h ($\text{AUC}_{0-10 \text{ h}}$) on days 1 and 5 of each treatment according to the trapezoidal rule, using a WinNonlin program (Ver. 3.1, Pharsight Co., Mountain View, CA, USA). The same program was used to simulate plasma 5-FU concentrations during treatment with S-1. AUCs were calculated on the basis of data obtained at the following time points; 0, 1, 2, 4, 6, and 10 h for S-1 on day 1; 0, 2, 4, and 10 h for S-1 on day 5; and 0, 2, 6, and 10 h for PVI of 5-FU on days 1 and 5.

DPD activity

DPD activity was determined by a catalytic assay as described by Ikenaka *et al* (1979). Blood samples were collected from patients before the start of 5-FU PVI, at about 0900 hours. Peripheral blood mononuclear cells (PBMC) prepared from about 10 ml of blood were thawed and placed in $250 \mu\text{l}$ of a homogenised buffer containing 10 mM Tris-HCl, 1 mM EDTA, and 0.5 mM dithiothreitol, pH 7.4. The PBMCs were then homogenised by sonication, and the homogenate was centrifuged at $105\,000 \text{ g}$ for 60 min (4°C). The supernatant fraction was collected as the enzyme source and was frozen and stored at -80°C until analysis.

RESULTS


Between April and October 2000, 10 male patients were enrolled. Their median age was 66 years (range, 45–75 years). All 10 patients had metastatic gastric carcinoma and eight had undergone gastrectomy. Two patients had previously received chemotherapy (irinotecan plus mitomycinC in 1, and cisplatin plus irinotecan in the other). The median body surface area (BSA) was 1.52 m^2 (range, $1.38\text{--}1.85 \text{ m}^2$). The initial doses of S-1 were $100 \text{ mg body}^{-1} \text{ day}^{-1}$ in four patients and $120 \text{ mg body}^{-1} \text{ day}^{-1}$ in six patients. The median actual dose of S-1 in the 10 patients was $71.6 \text{ mg m}^{-2} \text{ day}^{-1}$ (range, $64.8\text{--}80.0 \text{ mg m}^{-2} \text{ day}^{-1}$) (Table 1).

5-FU, uracil, and FBAL PK

The plasma concentrations of 5-FU, uracil, and FBAL after administration of PVI 5-FU and oral S-1 in the 10 patients on days 1–5 are shown in Figures 1 and 2. The plasma 5-FU concentration reached a steady state 2 h after the start of PVI. This steady state was maintained throughout the 5 days. During treatment with S-1, the time to the peak plasma concentration of 5-FU was 2–4 h. The C_{max} of 5-FU after S-1 treatment on day 1 was

Table 1 Pharmacokinetic parameters of 5-FU, uracil, and FBAL in 10 patients receiving PVI and S-1


	5-FU		Uracil		FBAL	
	Day 1	Day 5	Day 1	Day 5	Day 1	Day 5
C_{\max} (ng ml ⁻¹)						
PVI	93 ± 24	93 ± 13	24 ± 7	30 ± 9	858 ± 13	1157 ± 350
S-1	144 ± 33	230 ± 69	1262 ± 355	1559 ± 409	100 ± 69	198 ± 74
<i>P</i> -value ^a	0.004	<0.001	<0.001	<0.001	<0.001	<0.001
AUC (ng hr ml ⁻¹)						
PVI	733 ± 164	728 ± 113	200 ± 60	252 ± 60	6267 ± 113	9465 ± 3225
S-1	857 ± 209	1364 ± 374	9033 ± 2176	12582 ± 3060	767 ± 395	1725 ± 605
<i>P</i> -value ^a	0.181	<0.001	<0.001	<0.001	<0.001	<0.001

FBAL = F-β-alanine. ^aPaired *t*-test.**Figure 1** Plasma concentrations of 5-FU and uracil vs time after PVI of 5-FU and after oral S-1. Closed and open circles show the concentration of 5-FU and concentration of uracil, respectively. The left and right graphs show data for PVI of 5-FU and for S-1, respectively. Data are presented as means; bars, s.d.

lower than the C_{\max} of 5-FU on days 2–5 of S-1 treatment. The plasma concentration of uracil during S-1 treatment was higher than the baseline value.

The C_{\max} and AUC_{0-10h} of 5-FU in plasma during S-1 treatment were higher than the steady-state concentration and AUC_{0-10h} of 5-FU in plasma during PVI of 5-FU. On day 5, the median AUC_{0-10h} and C_{\max} of 5-FU with S-1 were 1.9- and 2.5-fold greater than the respective values with PVI of 5-FU.

The plasma FBAL concentration during S-1 treatment was markedly lower than that during PVI of 5-FU. On day 5, the AUC_{0-10h} of FBAL with PVI of 5-FU was 5.5-fold greater than that with S-1.

**Figure 2** Plasma concentration of FBAL vs time after PVI of 5-FU and after oral S-1. Closed and open circles show the plasma concentration of FBAL after S-1 and PVI of 5-FU, respectively. Data are presented as means; bars, s.d.

On day 1 of PVI of 5-FU, $1.2 \pm 0.7\%$ (range, 0.3–2.3%) and $39.2 \pm 11.3\%$ (range, 15.9–52.9%) of the administered dose was excreted in urine as 5-FU and FBAL, respectively. On day 1 of treatment with oral S-1, $7.3 \pm 2.2\%$ (range, 3.9–11.0%) and $21.7 \pm 6.6\%$ (range, 13.0–35.0%) of the administered dose were excreted in urine as 5-FU and FBAL, respectively.

The mean DPD activity of PBMC was $226 \text{ pmol min}^{-1} \text{ mg}^{-1}$ (range, 128–492 $\text{pmol min}^{-1} \text{ mg}^{-1}$). There was no correlation between the DPD activity of PBMC and the plasma concentration or AUC_{0-10h} of 5-FU.

DISCUSSION

This study showed that the C_{\max} and AUC_{0-10h} of 5-FU during treatment with oral S-1, given at dose levels recommended on the basis of phase I and II trials, were about two times greater than the respective values during PVI of 5-FU. Our results suggest that the higher incidence of leukopenia and diarrhoea associated with S-1, as compared with PVI of 5-FU, may be attributed to the significantly higher C_{\max} and AUC of plasma 5-FU (Thyss *et al*, 1986; Vokes *et al*, 1996; Van Groeningen *et al*, 2000). In the phase I trial with once daily administration schedule of S-1, pharmacodynamic analysis demonstrated a correlation between grade of diarrhoea and both C_{\max} of 5-FU ($r = 0.57$, $P < 0.05$) and AUC of 5-FU ($r = 0.74$, $P < 0.01$) (Cohen *et al*, 2002).

The plasma concentration of FBAL, the main catabolite of 5-FU, was significantly lower during S-1 treatment than during PVI of

5-FU. The AUC_{0-10h} of the plasma FBAL concentration on day 5 of PVI of 5-FU was five-fold higher than that on day 5 of treatment with S-1. The plasma uracil concentration increased during S-1 treatment. The C_{max} of uracil was attained 4 h after oral administration of S-1 and decreased at 10 h. These results provide evidence that CDHP reversibly inhibits DPD. Plasma levels of FBAL and uracil have also been measured in European phase I studies of S-1. Very low levels of FBAL were detected because of DPD inhibition in 4 patients given S-1 (Van Kuilenberg *et al*, 2001). This low level of FBAL in plasma may be responsible for the decreased incidence of neurotoxicity and cardiotoxicity associated with 5-FU. In fact, several phase I and II clinical trials of S-1 have reported no cardiotoxicity or neurotoxicity (Taguchi *et al*, 1997; Sakata *et al*, 1998; Sugimachi *et al*, 1999; Koizumi *et al*, 2000; Ohtsu *et al*, 2000; Cohen *et al*, 2002; Chollet *et al*, 2003; Hoff *et al*, 2003; Van den Brande *et al*, 2003).

Capecitabine is also an oral fluoropyrimidine derivative (Budman *et al*, 1998). When capecitabine was administered orally after meals at a dose of 1255 mg m^{-2} , the AUC of the plasma FBAL concentration was $31\,400 \text{ ng h ml}^{-1}$ (Reigner *et al*, 1998). This is 3.4-fold greater than the AUC of FBAL during PVI of 5-FU and 18-fold higher than that during treatment with oral S-1. The AUC of plasma 5-FU after treatment with capecitabine was 698 ng h ml^{-1} , and the C_{max} of plasma 5-FU was 310 ng ml^{-1} . The AUC of 5-FU was similar to that during PVI of 5-FU and about half that during treatment with S-1. The C_{max} of 5-FU was 3.3-fold higher than that during PVI of 5-FU and 1.3-fold higher than that during S-1 treatment. Thus, the AUC of the plasma FBAL concentration after oral capecitabine was much higher than that after oral S-1. In a randomised phase II trial of capecitabine in patients with metastatic colorectal cancer, the incidence of cardiotoxicity was 5% (five out of 108) (Van Cutsem *et al*, 2000). The treatment was discontinued in four patients because of chest pain, angina, or atrial fibrillation. Paresthesia occurred in 12% of the patients (Van Cutsem *et al*, 2000). The incidence of neurotoxicity was high, as compared with that during PVI of 5-FU or during treatment with S-1.

Capecitabine is associated with a high incidence of HFS, occurring in 45% of patients (Van Cutsem *et al*, 2000). The incidence of grade 3 HFS is 15–18% (Van Cutsem *et al*, 2000, 2001; Hoff *et al*, 2001). Hand-foot syndrome is also a major problem

during PVI of 5-FU with a reported incidence of about 23% (Lokich *et al*, 1989). S-1 has a very low incidence of HFS (Taguchi *et al*, 1997; Sakata *et al*, 1998; Sugimachi *et al*, 1999; Koizumi *et al*, 2000; Ohtsu *et al*, 2000; Van Groeningen *et al*, 2000; Cohen *et al*, 2002; Hoff *et al*, 2003; Peters *et al*, 2003). Hand-foot syndrome has been observed in just eight out of 3808 mainly Asian patients (0.2%) treated with S-1, according to the safety database of the manufacturer of this compound, Taiho Pharmaceuticals. In addition, HFS occurred in 9–10% in European phase II trial; however, most of the cases were limited to grade 1–2 (Chollet *et al*, 2003; Van den Brande *et al*, 2003). Interestingly, a low incidence of HFS has also been reported for eniluracil, an irreversible DPD inhibitor, plus oral 5-FU (Mani *et al*, 2000). Only two of 55 patients (4%) treated with oral 5-FU plus eniluracil had mild HFS. These findings suggest that the degree of DPD inhibition may correlate with the frequency and grade of HFS. Although the mechanism of HFS remains unknown, it may occur secondarily to the formation of 5-FU catabolites. Owing to modulation at the DPD level, 5-FU catabolites are less likely to form during treatment with S-1 and oral 5-FU plus eniluracil, as compared with capecitabine. However, we have no direct evidence showing that FBAL causes HFS.

In conclusion, we found that oral S-1 at presently recommended doses produced a higher C_{max} and a greater AUC of plasma 5-FU than did PVI of 5-FU, with no elevation of the plasma FBAL concentration. During S-1 treatment, DPD inhibition by CDHP apparently resulted in lower plasma FBAL concentrations and higher plasma uracil concentrations than did PVI of 5-FU.

ACKNOWLEDGEMENTS

We thank Hideko Morita, Mari Araake, Yasuo Mizumura, Yoshihisa Tsukioka, Saori Hayashi, Chigusa Morizane, Haruyasu Murakami, and Yasuhito Fujisaka for assistance with data collection. We also acknowledge the support of Nobutaka Samejima, Yoshihiro Mizokami, Naruo Nomura, Makiko Shinogi, and Hiromi Orita, without whom we would have been unable to complete this study. This research was supported by a grant from the Ministry of Health, Labor, and Welfare, Japan.

REFERENCES

- Budman DR, Meropol NJ, Reigner B, Creaven PJ, Lichtman SM, Berghorn E, Behr J, Gordon RJ, Osterwalder B, Griffin T (1998) Preliminary studies of a novel fluoropyrimidine carbamate: capecitabine. *J Clin Oncol* **16**: 1795–1802
- Chollet P, Schoffski P, Weigang-Kohler K, Schellens JHM, Cure H, Pavlidis N, Grunwald V, De Boer R, Wanders J, Fumoleau P (2003) Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC early clinical studies group (ECSG). *Eur J Cancer* **39**: 1264–1270
- Cohen SJ, Leichman CG, Yeslow G, Beard M, Proefrock A, Roedig B, Damle B, Letrent SP, DeCillis AP, Meropol NJ (2002) Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer. *Clin Cancer Res* **8**: 2116–2122
- Diasio RB (1998) The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. *Oncology* **12**: 23–27
- Hoff PM, Ansari R, Batist G, Cox J, Kocha W, Kuperminc M, Maroun J, Walde D, Weaver C, Harrison E, Burger HU, Osterwalder B, Wong AO, Wong R (2001) Comparison of oral capecitabine *versus* intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. *J Clin Oncol* **19**: 2282–2292
- Hoff PM, Saad ED, Ajani JA, Lassere Y, Wenske C, Medgyesy D, Dwivedy S, Russo M, Pazdur R (2003) Phase I study with pharmacokinetics of S-1 on an oral daily schedule for 28 days in patients with solid tumors. *Clin Cancer Res* **9**: 134–142
- Ikenaka K, Shirasaka T, Kitano S, Fujii S (1979) Effect of uracil on the metabolism of 5-fluorouracil *in vitro*. *Gann* **70**: 353–359
- Kato T, Shimamoto Y, Uchida J, Ohshimo H, Abe M, Shirasaka T, Fukushima M (2001) Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5-fluorouracil. *Anticancer Res* **21**: 1705–1712
- Koenig H, Patel A (1970) Biochemical basis for fluorouracil neurotoxicity. *Arch Neurol* **23**: 155–160
- Koizumi W, Kurihara M, Nakano S, Hasegawa K (2000) Phase II study of S-1, a novel oral derivative of 5-fluorouracil, in advanced gastric cancer. *Oncology* **58**: 191–197
- Kuwata K, Nagayama S, Hirakawa Y, Matsushima E, Kawaguchi Y (2000) Comparison of pharmacokinetics of 5-FU and F- β -alanine, a metabolite of 5-FU, in plasma after administration of UFT, tegafur, 5-FU or doxifluridine to rats. *Jpn J Cancer Chemother* **27**: 885–890
- Lokich JJ, Ahlgren JD, Gullo JJ, Phillips JA, Fryer JG (1989) A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a mid-Atlantic oncology program study. *J Clin Oncol* **7**: 425–432
- Mani S, Hochster H, Beck T, Cheven EM, O'Rourke MA, Weaver CH, Bell WN, White R, McGuirt C, Levin J, Hohnaker J, Schilsky RL, Lokich J

- (2000) Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer. *J Clin Oncol* **18**: 2894–2901
- Matsushima E, Yoshida K, Kitamura R, Yoshida K (1997) Determination of S-1 (combined drug of tegafur, 5-chloro-2,4-dihydropyridine and potassium oxonate) and 5-fluorouracil in human plasma and urine using high-performance liquid chromatography and gas chromatography–negative ion chemical ionization mass spectrometry. *J Chromatogr B Biomed Sci Appl* **691**: 95–104
- Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, Taguchi T (2000) Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. *Br J Cancer* **83**: 141–145
- Okeda R, Shibutani M, Matsuo T, Kuroiwa T, Shimokawa R, Tajima T (1990) Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetic acid and α -fluoro- β -alanine. *Acta Neuropathol* **81**: 66–73
- Peters GJ, Noordhuis P, Van Kuilenburg ABP, Schornagel JH, Gall H, Turner SL, Swart MS, Voorn D, Van Gennip AH, Wanders J, Holwerda U, Smid K, Giaccone G, Fumoleau P, Van Groeningen CJ (2003) Pharmacokinetics of S-1, an oral formulation of fluorouracil, oxonic acid and 5-chloro-2,4-dihydropyridine (molar ratio 1:0.4:1) in patients with solid tumors. *Cancer Chemother Pharmacol* **52**: 1–12
- Reigner B, Verweij J, Dirix L, Cassidy J, Twelves C, Allman D, Weidekamm E, Roos B, Banken L, Utoh M, Osterwalder B (1998) Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. *Clin Cancer Res* **4**: 941–948
- Robben NC, Pippas AW, Moore JO (1993) The syndrome of 5-fluorouracil cardiotoxicity. *Cancer* **71**: 493–509
- Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T (1998) Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur–0.4 M gimestatin–1 M oxotat potassium) in advanced gastric cancer patients. *Eur J Cancer* **34**: 1715–1721
- Sugimachi K, Maehara Y, Horikoshi N, Shimada Y, Sakata Y, Mitachi Y, Taguchi T (1999) An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. *Oncology* **57**: 202–210
- Taguchi T, Inuyama Y, Kanamaru R, Hasegawa K, Akazawa S, Niitani H, Furue H, Kurihara M, Ota K, Suga S, Ariyoshi Y, Takai S, Shimoyama T, Toge T, Takashima S, Sugimachi K, Hara Y, Fujita H, Kimura K, Saito T, Tsukagoshi S, Nakao I (1997) Phase I study of S-1. *Jpn J Cancer Chemother* **24**: 2253–2264
- The Meta-Analysis Group in Cancer (1998) Toxicity of fluorouracil in patients with advanced colorectal cancer. *Effect of administration schedule and prognostic factors*. *J Clin Oncol* **16**: 3537–3541
- Thyss A, Milano G, Renee N, Vallicioni J, Schneider M (1986) Clinical pharmacokinetic studies of 5FU in continuous 5-day infusions for head and neck cancer. *Cancer Chemother Pharmacol* **16**: 64–66
- Van Cutsem E, Findlay M, Osterwalder B, Kocha W, Dalley D, Pazdur R, Cassidy J, Dirix L, Twelves C, Allman D, Bajetta E, Boyer M, Bugat R, Findlay M, Frings S, Jahn M, McKendrick J, Osterwalder B, Perez-Manga G, Rosso R, Rougier P, Shmigel WH, Seitz J-F, Thompson P, Vieitez JM, Weitzel C, Harper P for the Xeloda Colorectal Cancer Study (2001) Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. *J Clin Oncol* **19**: 4097–4106
- Van den Brande, Schoffski P, Schellens JHM, Roth AD, Duffaud F, Weigang-Kohler K, Reinke F, Wanders J, De Boer RF, Vermorken JB, Fumoleau P (2003) EORTC early clinical studies group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer. *Br J Cancer* **88**: 648–653
- Van Groeningen CJ, Peters GJ, Schornagel JH, Gall H, Noordhuis P, de Vries MJ, Turner SL, Swart MS, Pinedo HM, Hanauske AR, Giaccone G (2000) Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. *J Clin Oncol* **18**: 2772–2779
- Van Kuilenburg ABP, Stroomer AEM, Peters GJ, Van Gennip AH (2001) Simultaneous determination of F- β -alanine and β -alanine in plasma and urine with dual-column reversed-phase high-performance liquid chromatography. *J Chromatogr* **759B**: 51–61
- Vokes EE, Mick R, Kies MS, Dolan ME, Malone D, Athanasiadis I, Haraf DJ, Kosloff M, Weichselbaum RR, Ratain MJ (1996) Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer. *J Clin Oncol* **14**: 1663–1671